QELBREE: payments to doctors
Payments that named QELBREE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $16.1M
- Providers
- 37,973
- Transactions
- 257,119
- Average per transaction
- $62
The per-transaction average — $62 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 37,973 providers the average total is $423, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | $16,005,563 | 99.7% |
| MDD US Operations, LLC | $53,341 | 0.3% |